Patents Assigned to Canbas Co., Ltd.
  • Publication number: 20050059116
    Abstract: The invention provides compositions and methods for inhibiting Chk1 and/or Chk2 kinases. Also provided are compositions and methods for inhibiting G2 cell arrest checkpoint, particularly in mammalian, e.g., human, cells. The compositions and methods of the invention are also used to treat disorders of cell growth, such as cancer. In particular, the invention provides methods for selectively sensitizing G1 checkpoint impaired cancer cells to DNA damaging agents and treatments. Also provided are methods for screening for compounds able to interact with, e.g., inhibit, enzymes involved in the G2 cell cycle arrest checkpoint, such as Chk1 and/or Chk2/Cds1 kinase.
    Type: Application
    Filed: October 15, 2004
    Publication date: March 17, 2005
    Applicant: CanBas Co. Ltd.
    Inventors: Masashi Suganuma, Takumi Kawabe
  • Publication number: 20040248783
    Abstract: This invention provides compounds including peptides and peptidomimetics that can be used to treat cell proliferative disorders, such as those associated with benign and malignant tumor cells. While the invention is not limited to any particular mechanism, the compounds of the invention appear to function at least in part by inhibiting G2 cell cycle checkpoint. Thus, invention compounds can be used to inhibit cell growth alone or be used in combination with a nucleic acid damaging treatment to inhibit cell growth.
    Type: Application
    Filed: January 17, 2003
    Publication date: December 9, 2004
    Applicant: CanBas Co., Ltd.
    Inventors: Takumi Kawabe, Hidetaka Kobayashi